Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, Walter Reinisch, Joo Sung Kim et al.|The Lancet|2017Cited by 198
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA studyWilliam J. Sandborn, Geert D’Haens, Scott D. Lee et al.|Gut|2017Cited by 107
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA StudyGeert D’Haens, Olaf Stüve, Séverine Vermeire et al.|Journal of Crohn s and Colitis|2017Cited by 28
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn’s DiseaseMina Hassan‐Zahraee, Kenneth E. Hung, Anindita Banerjee et al.|Journal of Crohn s and Colitis|2017Cited by 26
Anti-MAdCAM-1 therapy does not affect immune surveillance in the central nervous systemOlaf Stüve, Ken Gorelick, Geert D’Haens et al.|The Journal of Immunology|2016Cited by 0